Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

ARNA 4.17 +0.07 (1.71%)
price chart
Could Arena Pharmaceuticals Inc. Be Running Out of Money?
With Wall Street not expecting the company to be profitable on annual basis until 2017, it's worth digging beyond the surface to discover whether or not Arena Pharmaceuticals could be running out of money. Today we'll do just that, as well as look at ...
Related articles »  
Arena Investors Need To Watch Contrave Launch Closely
Arena Pharmaceuticals (NASDAQ:ARNA) investors now have something else to pay attention to. Orexigen ... Eisai may need to at some point, but I expect the company to be conservative and to collect some data before jumping to a rash conclusion.
Sizzling Stock Alert: Novavax, Inc. (NVAX), Arena Pharmaceuticals, Inc.(ARNA ...
Manhattan, NY- October 24, 2014 - (Techsonian) - Novavax, Inc. (NASDAQ:NVAX)revealed that Gregory Glenn, M.D., Senior Vice President, Research and Development at Novavax will present new immunogenicity data from Novavax' RSV F-Protein ...
Related articles »  
Pharma Stocks to Watch: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Monday said data from phase 3 clinical trials of its obesity drug BELVIQ (lorcaserin HCl) will be presented at the American College of Clinical Pharmacy meeting taking place through Wednesday of this week.
Related articles »  
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA ...
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and ...
Related articles »  
4 High-Gross Margin Stocks: Arena Pharmaceuticals, Inc. (ARNA), Gastar ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has return on equity ratio of -54.10%. The company has $881.56 million in market worth.
Related articles »  
Pfizer Setback Could Help Arena
It was only a month ago that the company received positive indications from the FDA when the regulators agreed to a new label for the drug that was less stringent than the earlier label.
Related articles »  
Belviq Sales Flat - Model Your Expectations (ARNA)
Sales of Arena Pharmaceuticals' (NASDAQ:ARNA) Belviq were essentially flat this week vs. last week, according to industry tracker IMS Health (NYSE:IMS).
Related articles »  
Momentum Stocks: Ariad Pharmaceuticals Inc. (ARIA), Arena Pharmaceuticals ...
The average volume for Ariad Pharmaceuticals Inc. (NADSAQ:ARIA) has been 7.4 million shares per day over the past 30 days. Ariad Pharmaceuticals Inc. (NADSAQ:ARIA) stock opened with a price of $5.65 and hit a high of $5.68 with a low of $5.55 today.
Hot Stocks Alert: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Sunesis ...
Eisai Inc. and Arena Pharmaceuticals, Inc. (ARNA) announced that data from the Phase 3 clinical trial program for BELVIQ (lorcaserin HCl) CIV was scheduled to be presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting taking place ...
Stocks Trending Alert-CEL-SCI (NYSEMKT:CVM), Arena Pharmaceuticals ...  Techsonian (press release)
Related articles »